Eli Lilly Joins ImmunoGen’s List of Big Pharma Collaborators

By Heather Cartwright

Pharma Deals Review: Vol 2012 Issue 1 (Table of Contents)

Published: 6 Jan-2012

DOI: 10.3833/pdr.v2012.i1.1648     ISSN: 1756-7874

Section: Technology Access

Fulltext:

Abstract

Eli Lilly has gained rights to use ImmunoGen’s maytansinoid targeted antibody payload (TAP) technology to develop a specified number of antibody-drug conjugates for the potential treatment of cancer...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details